Molecular and Immunological Effect of Propofol in Relieving Myocardial Ischemia-Reperfusion Injury in Type 2 Diabetic Patients
Molecular and Immunological Effect of Propofol in Relieving Myocardial Ischemia-Reperfusion Injury in Type 2 Diabetic Patients
Caiping Duan
ABSTRACT
This study aimed to explore the clinical mechanism of propofol in relieving myocardial ischemia-reperfusion injury in type 2 diabetic patients. In the present study, 369 patients suffering from myocardial ischemia-reperfusion injury who were diagnosed with type 2 diabetes in our hospital from January 2018 to May 2019 were selected as study subjects and randomly divided into low-dose propofol group (n=123; intravenously injected with 25 mg before angiography), high-dose propofol group (n=123; intravenously injected with 50 mg before angiography) and control group (n=123; receiving local anesthesia before angiography, subcutaneously injected with 2% lidocaine 2.5 ml at puncture point). After coronary angiography in each group, the serum nitric oxide (NO), endothelin-1 (ET-1) and cardiac troponin (cTnT) contents in different treatment groups were detected by enzyme-linked immunosorbent assay. Coronary blood samples were obtained during coronary angiography. Expressions of interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF -α) were detected by Western blotting (WB). The protein contents of B-cell lymphoma factor 2 (Bcl-2), apoptosis-related genes Bax and caspase-3 were detected by WB. The contents of lactic dehydrogenase (LDH), creatine kinase (CK), superoxide dismutase (SOD) and malondialdehyde (MDA) were detected by enzyme-linked immunosorbent assay. Results showed that compared with the control group, the low-dose propofol group had increased NO, decreased ET-1 and cTnT contents (P<0.05), and high-dose propofol group had further increased NO and further decreased ET- 1 and cTnT contents compared with low-dose propofol group (P<0.05). Compared with the control group, the low-dose propofol group had reduced IL-1β, IL-6 and TNF-α expressions (P<0.05), and high-dose propofol group had further reduced IL-1β, IL-6 and TNF-α expressions compared with low-dose propofol group (P<0.05). Compared with the control group, the low-dose propofol group had increased Bcl-2 protein content, decreased Bax and Caspase-3 protein contents (P<0.05); compared with low-dose propofol group, high-dose propofol group had further increased Bcl-2 protein content, further decreased Bax and Caspase-3 protein contents (P<0.05). Compared with the control group, low-dose propofol group had decreased SOD content, increased LDH, CK, and MAD contents (P<0.05). Compared with low-dose propofol group, high-dose propofol group had further decreased SOD content, further increased LDH, CK and MAD contents (P<0.05). We conclude that, Propofol has a protective effect on myocardial ischemia-reperfusion injury in type 2 diabetic patients, the mechanism of which is to up-regulate serum NO, Bcl-2 and SOD, and down-regulate serum ET-1, cTnT, IL-1β, IL-6, TNF-α, BAX, LDA, CK, MAD, thus protecting cardiomyocytes.
To share on other social networks, click on any share button. What are these?
